Key Highlights

  • Mobile-health Network Solutions (NASDAQ:MNDR) fell 25.00% pre-market after an unexplained spike, with a Market Value of USD 4 million and an RSI of 73.2, on 1,082,812 shares, on 1,082,812 shares, on 1,082,812 shares, on 1,082,812 shares.
  • Syndax Pharmaceuticals (NASDAQ:SNDX) fell 14.02% pre-market after an IPF trial miss, with a market value of USD 1.48 billion and an RSI of 34.3, on 30,136 shares, on 30,136 shares, on 30,136 shares, on 30,136 shares.
  • MacroGenics (NASDAQ:MGNX) fell 7.80% pre-market despite USD 327 million of pro forma cash, with a market value of USD 237 million and an RSI of 45.6, on 1,238 shares, on 1,238 shares, on 1,238 shares.
  • Six Flags Entertainment (NYSE:FUN) fell 7.55% pre-market on heavy debt, with a market value of USD 1.22 billion and an RSI of 42.4, on 49,536 shares, on 49,536 shares, on 49,536 shares, on 49,536 shares.

Mobile-health Network Solutions (NASDAQ:MNDR): Spike Unwinds Pre-Market

Mobile-health Network Solutions (NASDAQ:MNDR) fell 25.00% pre-market to a listed USD 3.04 on 1,082,812 shares, with a market Capitalization of USD 4 million and an RSI of 73.2 labeled Up, overbought. Mobile-health Network Solutions fell 25.00% pre-market after a roughly 370% spike on October 12, with no catalyst found, on 1.083 million shares. The stock closed near USD 0.85 on October 9 and traded as high as about USD 4 on October 12, so the pre-market price is still far above that close. The company completed a one-for-five reverse split in September 2025, Revenue is about USD 7.3 million to USD 7.6 million, and cash is near USD 1.03 million. The RSI of 73.2 is flagged overbought and the 52-week range runs from USD 0.76 to USD 32.52. A USD 4 million market value and a reverse-split history mean the unwind can be as violent as the spike. By market value it ranks 5 of 5 in this group. What to watch next: regular-session Volume and filings.

Syndax Pharmaceuticals (NASDAQ:SNDX): IPF Miss Hits the Stock

Syndax Pharmaceuticals (NASDAQ:SNDX) fell 14.02% pre-market to a listed USD 16.55 on 30,136 shares, with a market capitalization of USD 1.48 billion and an RSI of 34.3 labeled Down. Syndax fell 14.02% pre-market after saying its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis, which ends its plans to advance the drug in IPF. The company said the result does not affect ongoing trials of the same drug in other settings, and axatilimab is already approved and sold as Niktimvo for chronic graft-versus-host disease. Axatilimab did not slow lung function decline better than placebo, and secondary measures such as time to progression and quality of life showed no benefit. The stock closed at USD 16.55 on October 12 against a 52-week range of USD 12.99 to USD 25.59, with an average analyst target near USD 37.55, and short interest is about 24.28% of the float. Losing an IPF opportunity removes one growth leg, so the stock now depends on Niktimvo sales and other trials. By market value it ranks 2 of 5 in this group. What to watch next: Niktimvo sales and the remaining axatilimab trials.

MacroGenics (NASDAQ:MGNX): Cash Above Market Value

MacroGenics (NASDAQ:MGNX) fell 7.80% pre-market to a listed USD 3.72 on 1,238 shares, with a market capitalization of USD 237 million and an RSI of 45.6 labeled Mixed. MacroGenics reported its second-quarter 2026 results on August 13, with total revenue of USD 32.8 million compared with USD 6.9 million a year earlier, helped by partner payments. In July it sold its Manufacturing operations to Bora Pharmaceuticals for USD 122.5 million, received USD 119.6 million in cash at closing and moved to a fully outsourced model with a workforce of about 140. Cash, cash equivalents and marketable securities were USD 173.3 million at June 30, 2026, or USD 327 million pro forma after proceeds from Bora, Sanofi and Gilead, with a runway through 2028. The pipeline includes MGC026, a B7-H3 antibody drug conjugate, MGC028, an ADAM9 conjugate with preliminary data planned for late 2026, lorigerlimab, a PD-1 by CTLA-4 antibody, and MGC030, whose IND was cleared ahead of schedule. Clinical-stage results are binary, partner payments are lumpy, and a market value below cash signals doubts about the pipeline. By market value it ranks 4 of 5 in this group. What to watch next: ESMO data, MGC028 results and the first MGC030 dosing.

Six Flags Entertainment (NYSE:FUN): USD 4.9 Billion Net Debt

Six Flags Entertainment (NYSE:FUN) fell 7.55% pre-market to a listed USD 11.92 on 49,536 shares, with a market capitalization of USD 1.22 billion and an RSI of 42.4 labeled Mixed. Six Flags reported second-quarter 2026 results on August 6, with net revenues of USD 865 million, down USD 65 million or 7.0%, and attendance of 13.1 million, down 7% as it sold or closed parks. On a same-park basis attendance rose 4% despite 44 fewer operating days, same-park net revenue rose 2% to about USD 864 million and same-park adjusted EBITDA rose about 7% to USD 249 million. Net Debt totaled USD 4.9 billion, calculated as total debt of USD 5.0 billion less USD 135 million of cash, and Liquidity was about USD 837 million including USD 703 million of revolver availability. Net interest expense was USD 102 million in the quarter, USD 197 million for the half, and management targets a net Leverage Ratio of 4.0 times over time. High leverage and interest costs leave little room for an attendance miss, and a news tag could not be matched to a filing. By market value it ranks 3 of 5 in this group. What to watch next: attendance, the pass base and deleveraging progress.

SentinelOne (NYSE:S): USD 1.25 Billion Convert

SentinelOne (NYSE:S) fell 7.01% pre-market to a listed USD 25.66 on 230,075 shares, with a market capitalization of USD 8.93 billion and an RSI of 63.3 labeled Strong up. SentinelOne fell 7.01% pre-market after announcing a USD 1.25 billion convertible debt offering and saying it is in talks for a USD 400 million revolving Credit facility. The screener tags the move as a capital raise. Convertible notes can dilute shareholders if converted and often come with hedging that pressures the stock. The market value is USD 8.93 billion, the RSI is 63.3 labeled Strong up, and the stock had gained into the announcement. Debt and dilution risk rise after a large convertible, and the stock tends to trade lower around such deals. By market value it ranks 1 of 5 in this group. What to watch next: the final pricing terms and use of proceeds.

Where Things Stand

The five biggest pre-market drops had very different causes: a spike unwind, a failed trial, a convertible offering, a news tag and no catalyst. Mobile-health Network Solutions (NASDAQ:MNDR) fell 25.00%. Syndax Pharmaceuticals (NASDAQ:SNDX) fell 14.02%. MacroGenics (NASDAQ:MGNX) fell 7.80%. Six Flags Entertainment (NYSE:FUN) fell 7.55%. SentinelOne (NYSE:S) fell 7.01%. Pre-market moves on thin volume often reverse, so the balance of evidence favors waiting for the open and for filings. Direction remains unknown, and each name carries its own risks. Verify the latest filings before acting, and treat the figures as a snapshot.